A global biopharma company, focusing on neurology and immunology.
Our business is strong. Total revenue grew to €5.3 billion in 2020. We are more than 7,600 people in all four corners of the globe, inspired by patients and driven by science.
UCB’s ambition is to transform the lives of people living with severe diseases. We focus on neurology and immunology disorders – putting patients at the center of our world. We are Inspired by Patients. Driven by Science.
UCB is continuously working to advance science and embrace new knowledge. We are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs, and practical solutions – so that they and their carers can get on with their lives
We recognise that radical changes are taking place in the eco-system of care and that we need to evolve accordingly to deliver on our vision. The key element of our evolution is to focus on the delivery of increased patient value.
There is no such thing as an “average patient”. We want to use all the tools, channels and scientific advances at our disposal to develop a better understanding of the various expressions of a disease and embed the real needs of specific patient populations in our science and innovation process.
That is why we support patient groups who provide valuable services to patient communities and understand what matters to people living with severe diseases.
We believe in partnership. Our scientists collaborate with leading researchers from academia and industry to advance science and deliver the solutions patients need. Our open approach to innovation equips us to meet today’s biggest healthcare challenges.